Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21986
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKatsimbri, P. P.en
dc.contributor.authorBamias, A. T.en
dc.contributor.authorFroudarakis, M. E.en
dc.contributor.authorPeponis, I. A.en
dc.contributor.authorConstantopoulos, S. H.en
dc.contributor.authorPavlidis, N. A.en
dc.date.accessioned2015-11-24T19:19:47Z-
dc.date.available2015-11-24T19:19:47Z-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21986-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subjectBronchial Neoplasms/*secondary/therapyen
dc.subjectColonic Neoplasms/pathologyen
dc.subjectDiagnosis, Differentialen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectKidney Neoplasms/pathologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrognosisen
dc.subjectStomach Neoplasms/pathologyen
dc.subjectSurvival Analysisen
dc.subjectUrinary Bladder Neoplasms/pathologyen
dc.titleEndobronchial metastases secondary to solid tumors: report of eight cases and review of the literatureen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10717334-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0169500299001348/1-s2.0-S0169500299001348-main.pdf?_tid=65a7eea985f0f05034c10583434e4645&acdnat=1333611874_f64cf090d8304de0bce4d224fcc467ef-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractEndobronchial metastases (EBM) secondaries to extrapulmonary solid malignant tumors are rare. Breast, colon and renal adenocarcinomas are the most frequent tumors associated with EBM. Since 1990 we have treated eight patients with EBM secondary to renal adenocarcinoma (three cases), colon adenocarcinoma (two cases), gastric adenocarcinoma (one case), bladder carcinoma (one case) and basal cell carcinoma (one case). Endobronchial lesions were detected by bronchoscopy and their metastatic nature was confirmed histopathologically in all eight cases. We also conducted a review of EBM reporting studies published in English language. The median interval from the diagnosis of the primary tumour was 41 months. Symptoms and radiological findings were indistinguishable from those of primary lung cancer. Five patients were treated with external radiotherapy with symptomatic improvement while two patients had chemotherapy and one patient underwent surgical resection of the metastasis. Systemic treatment was used in six cases with no significant effect on EBM. Median survival after EBM diagnosis was 9 months with one patient surviving 3.5 years and two patients still alive at 1 year. In conclusion, EBM usually represent a late manifestation requiring differential diagnosis from a primary lung cancer. Local treatment may result in symptomatic improvement but prognosis is generally poor averaging 1-2 years in most series.en
heal.journalNameLung Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Katsimbri-2000-Endobronchial metast.pdf181.09 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons